Business
GeoVax Applauds White House Executive Order Supporting U.S. Pharmaceutical Manufacturing; Highlights Progress in Domestic MVA Vaccine Production
Company's Advanced Manufacturing Proposal Supports National Biosecurity Goals and Executive Action on Domestic Pharmaceutical Supply Chains ATLANTA, GA - May 6, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology co...
About this update from Geovax Labs, Inc.
[{"type":"image","caption":"","headline":"GeoVax Labs Announces $1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules","size":{"original":{"width":140,"height":140,"url":"https://media.zenfs.com/en/newsmediawire_165/6b870301b9c37c9b2d12fc8f9b2a2ecc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/CK3y_RQaAtNDQGf8lPQXOQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTIxMDtjZj13ZWJw/https://media.zenfs.com/en/newsmediawire_165/6b870301b9c37c9b2d12fc8f9b2a2ecc","width":140,"height":140}}},{"type":"text","content":"Company's Advanced Manufacturing Proposal Supports National Biosecurity Goals and Executive Action on Domestic Pharmaceutical Supply Chains","length":143,"tagName":"p"},{"type":"text","content":"ATLANTA, GA - May 6, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against infectious diseases and solid tumors, today voiced strong support for the Executive Order signed by President Trump on May 5, 2025, aimed at restoring a robust U.S. pharmaceutical manufacturing base and reducing America's reliance on foreign supply chains.","length":424,"tagName":"p"},{"type":"text","content":"The Order directs the U.S. Food and Drug Administration (FDA), Environmental Protection Agency (EPA), and other agencies to streamline approvals for domestic pharmaceutical manufacturing, reduce foreign dependence, and fast-track U.S. supply chain resilience - a mission long championed by GeoVax. These actions align directly with GeoVax's commitment to strengthening U.S. biosecurity through domestic, scalable vaccine production technologies.","length":449,"tagName":"p"},{"type":"text","content":"David Dodd, Chairman and CEO of GeoVax, stated, "We commend the Administration's leadership in restoring America's pharmaceutical manufacturing independence. The COVID-19 pandemic and Mpox outbreaks exposed the fragility of foreign-dominated supply chains, particularly in vaccine manufacturing. GeoVax has taken a lead in addressing these risks with our U.S.-based GEO-MVA vaccine program and our advanced manufacturing process designed for national resiliency."","length":481,"tagName":"p"},{"type":"text","content":"Advancing U.S.-Based Biomanufacturing Through the RRPV","length":54,"tagName":"p"},{"type":"text","content":"In alignment with the Executive O...